Orphan drug applications skyrocket as Big Pharma carves out niche

01/31/2013 | Wall Street Journal, The

Rare diseases are being neglected to a much lesser degree as multinational drugmakers seek to take advantage of easier approval pathways and high prices for orphan drugs.

View Full Article in:

Wall Street Journal, The